Vaccination remains the main promising measure to fight against the COVID-19 pandemic.The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and95%. There is increasing evidence that sex-specific effects may lead to differentoutcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19vaccine are lacking. The first purpose of the study is to determine antibody titersagainst SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identifypredictor factors of immune response including age, gender and biological factors.
Not Provided
Inclusion Criteria:
- Any person, male or female, over 18 years of age who underwent vaccination and
- anti-SARS-CoV-2 serological test after vaccination
- having already given their consent for their biological resources to be:
- stored in a biocollection of the Microbiology Technical Platform (PTM) having
received an approval from the CPP Est-IV and declared to the Ministry of
Education and Research under reference No. DC2009-1002;
- subsequently reused, as well as the anonymized associated data, for research
purposes
Exclusion Criteria:
- Inability to give clear information (person in an emergency, difficulty
understanding the subject, etc.)
- Person under safeguard of justice
- Person under guardianship or curatorship-
Service de Virologie - Hôpital Civil
Strasbourg, France
Investigator: Samira FAFI-KREMER, PharmD, PhD
Contact: 33.3.69.55.14.38
Samira.fafi-kremer@chru-strasbourg.fr
Samira FAFI-KREMER, PharmD, PhD
33.3.69.55.14.38
Samira.fafi-kremer@chru-strasbourg.fr
Saïd CHAYER, PhD, HDR
33 3 88 11 66 90
said.chayer@chru-strasbourg.fr
Samira FAFI-KREMER, PharmD, PhD, Study Director
Service de Virologie - Hôpital Civil